

Latest Updates of Current Clinical Trials

University of Kansas Medical Center

➤ **Dr. Dimachkie – UCB Biopharma MG0003- Coordinator: Ali Ciersdorff**

- 18 weeks; 6 weekly treatment visits after initial baseline treatment, followed by an observation period
- 2/3 chance of receiving drug, 1/3 chance of receiving placebo
- Subcutaneous injection
- A 60-week Open-label is offered after the 18-week trial is complete – In the open-label all participants receive drug
- Payment: \$84 – baseline, visit 4, 5, 6, 8, and 9; completion of entire study participants will receive up to \$504
- Travel reimbursement is \$53 per visit up \$742 (this includes gas, food, hotel, etc.)

Eligibility Criteria:

- Positive serology for AChR or MUSK autoantibodies (Sero+ MG)
- No active or untreated thymoma, and no thymectomy within the past 6 months
- No use of the following within the time period specified below:
 - IV immunoglobulin within 4 weeks of Baseline
 - Use of plasma exchange within 4 weeks of Baseline
 - Use of rituximab or any other “Mabs” within 6 months of screening

➤ **Dr. Dimachkie – Alexion- Coordinator: Katie Jennens**

- 26 Weeks – 9 study visits
- 50% chance receiving drug, 50% chance of receiving placebo
- 5 weekly visits, come back a month after the 5th visit for the 6th visit, visits 7-10 are every 2 weeks, visits 11 and 12 are monthly
- Infusion at study visit 2, 4, 8, and 11
- After the 26 weeks, patients will enroll in “Open-Label”, meaning all patients will receive drug
- Up to \$50 reimbursement

Eligibility Criteria:

- Positive serology for AChR autoantibodies (Sero+ MG)
- No active or untreated thymoma, and no thymectomy within past 12 months
- No use of the following within the time period specified below:
 - IV immunoglobulin within 4 weeks of randomization
 - Use of plasma exchange within 4 weeks of randomization
 - Use of rituximab within 6 months of screening

➤ **Dr. Farmakidis – Ra Pharma – Coordinator: Samantha Colgan**

- 16 weeks – 7 study visits (including screening)
- 50% chance receiving drug, 50% chance of receiving placebo
- Self-administered daily injections
- After screening, 3 weekly visits, 4th visit is 2 weeks after visit 3, 5th visit is one month after visit 4, 6th visit is one month after visit 5
- After the 12 weeks, patients will enroll in “Open-Label”, meaning all patients will receive drug
- \$45 per visit, mileage reimbursement depending on distance

Eligibility Criteria:

- Positive serology for AChR autoantibodies (Sero+ MG)
- No change in corticosteroid dose for at least 30 days prior to treatment
- No change in immunosuppressive therapy for at least 30 days prior to treatment
- No Thymectomy within past 12 months

Washington University School of Medicine in St. Louis

➤ **MGChampion Study/Alexion 306**

This study is looking at an experimental drug called Ravulizumab, which is given through an IV infusion. This is a randomized control trial in which patients receive either the investigational drug or placebo every 8 weeks for 26 weeks. Once treatment starts the visits are about every 8 weeks and there are some remote options they’ve made available to patients once on treatment. After the first 26 weeks are complete participants will then rollover into an open-label extension where all the patients will be able to receive Ravulizumab. If anyone is interested, they are more than welcome to contact me directly at smith.june@wustl.edu

Study Website- <https://mgchampion.com/>

Clinicaltrials.gov- <https://clinicaltrials.gov/ct2/show/NCT03920293>

➤ **MycaringMG/UCB MG0003**

This study is looking at an experimental drug called Rozanolixizumab, which is given through a subcutaneous infusion. This is also a randomized control trial in which the patients receive either the investigational drug or placebo. The infusions are given weekly. This study is 18 weeks with 6 infusions than an observation period. Once completed the participants are given the option to enroll in a separate open-label extension study which would include infusions with the investigational drug. Anyone interested can contact me directly at smith.june@wustl.edu

Study Website- <https://www.mycaringstudy.com/>
Clinicaltrials.gov <https://clinicaltrials.gov/ct2/show/NCT03971422>